A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.

Kobuchi, Shinji; Tsuda, Motoi; Okamura, Maki; Nakamura, Takanori; Ito, Yukako

Kobuchi, Shinji; Tsuda, Motoi; Okamura, Maki; Nakamura, Takanori; Ito, Yukako.

Afiliação

Kobuchi S; Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Tsuda M; Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Okamura M; Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Nakamura T; Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Ito Y; Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan yukako@mb.kyoto-phu.ac.jp.

Anticancer Res ; 43(3): 1121-1130, 2023 Mar.

Article em En | MEDLINE | ID: mdl-36854515

Assuntos

Neoplasias Colorretais; Tegafur; Animais; Ratos; Uracila/farmacologia; Fluoruracila/farmacologia; Administração Oral; Neoplasias Colorretais/tratamento farmacológico

Palavras-chave

Preclinical pharmacokinetics; cancer chemotherapy; pharmacometrics; prodrug(s); therapeutic drug monitoring

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google